Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Intracellular Trafficking Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SNX16 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SNX16 Recombinant Protein (PX Domain / Full Length) High purity (>95%), Endotoxin Controlled. Sequence Verified. Theoretical MW confirmed by SDS-PAGE. |
View SNX16 Products |
| Gene Delivery | SNX16 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and intracellular trafficking visualization. |
View SNX16 Products |
| Benchmark Ab | Anti-SNX16 Recombinant Antibody Recombinant positive control for Western Blot, IHC, and Immunofluorescence. |
View SNX16 Products |
| Validator | SNX16 siRNA Set For specific knockdown verification in functional phenotypic assays. |
View SNX16 Products |
| Related Target A | EGFR SNX16 directly regulates EGFR endosome-to-lysosome trafficking and downstream signaling attenuation. |
View EGFR Products |
| Related Target B | CTNNB1 SNX16 modulates Wnt/beta-catenin signaling by regulating the trafficking of key pathway components. |
View CTNNB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Target Accessibility & Conformation | Lentivirus-mediated stable overexpression preserves native PX-domain conformation and phosphatidylinositol binding. |
| Phosphatidylinositol Binding Specificity (PI3P) | Sequence-verified PX domain recombinant proteins expressed with high purity (>95%) for liposome-binding assays. |
| Lack of Controls | Sequence-derived recombinant benchmark antibodies included for high-reproducibility tracking. |
| False Positives in Phenotypic Screening | Validated siRNA pooling included for target-specific knockdown verification. |
Live SNX16 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Sorting Nexin 16 (SNX16) is emerging as a compelling frontier in oncology and viral entry inhibition. As a key regulator of endosomal sorting, SNX16 orchestrates the trafficking, recycling, and degradation of critical receptor tyrosine kinases (RTKs) such as EGFR. The race for SNX16 therapeutics is intensifying, with major players shifting focus from traditional systemic pathway inhibition to precise intracellular trafficking modulation. As first-generation endosomal targeted therapies reach the clinic, the next wave of R&D is targeting the disruption of the SNX16-PX domain interaction with specific lipid membranes to arrest tumor cell migration and overcome RTK-targeted therapy resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | Colorectal Cancer, Hepatocellular Carcinoma | Lipid-protein binding assay (Need high-purity PX domain recombinant proteins) |
| PROTAC / Degraders | Targeted Protein Degradation Pioneers | EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) | Target degradation kinetics (Need Lentivirus for stable cell lines & benchmark antibodies) |
| RNA Therapeutics (siRNA/ASO) | RNAi Therapeutics Developers | Metastatic Solid Tumors | Phenotypic validation (Need validated siRNA sets and high-specificity control antibodies) |